ArticleScientific reports2025
Computational design of an mRNA vaccine targeting antifungal-resistant Lomentospora prolificans.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Targeting Amastigote and Trypomastigote Phases: Multi-Epitope Vaccine Strategy Against Trypanosoma cruzi.Biotechnology and applied biochemistry · 2026Article
- Protein engineering: status report.Protein engineering, design & selection : PEDS · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Lomentospora prolificans is an emerging opportunistic pathogen that predominantly affects immunocompromised individuals, as well as healthy individuals, often leading to disseminated disease with high mortality rates. Effective treatment is challenging due to its high intrinsic resistance to antifungal agents. To address this, we employed subtractive proteomics and reverse vaccinology approaches to identify potential antigenic proteins for the design of an mRNA-based multi-epitope vaccine (MEV). Our study identified four antigenic proteins as promising vaccine targets. A vaccine construct was developed using a combination of twelve cytotoxic T lymphocyte (CTL), nine helper T lymphocyte (HTL), and five linear B lymphocyte (LBL) epitopes. These epitopes were connected using appropriate linkers (AAY, GPGPG, and KK) and adjuvants to enhance antigenicity and immunogenicity. The vaccine construct was rigorously evaluated for its physicochemical properties, demonstrating high antigenicity, non-toxicity, non-allergenicity, stability, and solubility. Molecular docking studies were conducted to validate the interactions between the vaccine construct and the human toll-like receptor (TLR4). Immune simulation studies further confirmed the vaccine's potential to elicit a robust immune response. Additionally, molecular dynamics (MD) simulations, principal component analysis (PCA), dynamic cross-correlation matrix (DCCM) analysis, and binding free energy calculations were performed to assess the stability and efficacy of the vaccine-receptor complex. Codon optimization and in-silico cloning were carried out to ensure efficient expression of the vaccine in Escherichia coli strain K12. The findings of this study suggest that the proposed vaccine construct holds significant promise as a novel mRNA-based therapeutic candidate against L. prolificans infections. Further experimental validation is recommended to advance this vaccine toward clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.